CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Abstract The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 (http://www.cvot.org)..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Cardiovascular diabetology - 22(2023), 1 vom: 16. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schnell, Oliver [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Cardiovascular disease |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s12933-023-01788-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR049714457 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR049714457 | ||
| 003 | DE-627 | ||
| 005 | 20230323112955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230323s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12933-023-01788-6 |2 doi | |
| 035 | |a (DE-627)SPR049714457 | ||
| 035 | |a (SPR)s12933-023-01788-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schnell, Oliver |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Abstract The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 (http://www.cvot.org). | ||
| 650 | 4 | |a Cardiovascular disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chronic kidney disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Diabetes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GIP/GLP-1 receptor agonist |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Heart failure |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Obesity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SGLT2 inhibitor |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Battelino, Tadej |4 aut | |
| 700 | 1 | |a Bergenstal, Richard |4 aut | |
| 700 | 1 | |a Birkenfeld, Andreas L. |4 aut | |
| 700 | 1 | |a Ceriello, Antonio |4 aut | |
| 700 | 1 | |a Cheng, Alice |4 aut | |
| 700 | 1 | |a Davies, Melanie |4 aut | |
| 700 | 1 | |a Edelman, Steve |4 aut | |
| 700 | 1 | |a Forst, Thomas |4 aut | |
| 700 | 1 | |a Giorgino, Francesco |4 aut | |
| 700 | 1 | |a Green, Jennifer |4 aut | |
| 700 | 1 | |a Groop, Per-Henrik |4 aut | |
| 700 | 1 | |a Hadjadj, Samy |4 aut | |
| 700 | 1 | |a J.L.Heerspink, Hiddo |4 aut | |
| 700 | 1 | |a Hompesch, Marcus |4 aut | |
| 700 | 1 | |a Izthak, Baruch |4 aut | |
| 700 | 1 | |a Ji, Linong |4 aut | |
| 700 | 1 | |a Kanumilli, Naresh |4 aut | |
| 700 | 1 | |a Mankovsky, Boris |4 aut | |
| 700 | 1 | |a Mathieu, Chantal |4 aut | |
| 700 | 1 | |a Miszon, Martin |4 aut | |
| 700 | 1 | |a Mustafa, Reem |4 aut | |
| 700 | 1 | |a Nauck, Michael |4 aut | |
| 700 | 1 | |a Pecoits-Filho, Roberto |4 aut | |
| 700 | 1 | |a Pettus, Jeremy |4 aut | |
| 700 | 1 | |a Ranta, Kari |4 aut | |
| 700 | 1 | |a Rodbard, Helena W. |4 aut | |
| 700 | 1 | |a Rossing, Peter |4 aut | |
| 700 | 1 | |a Ryden, Lars |4 aut | |
| 700 | 1 | |a Schumm-Draeger, Petra-Maria |4 aut | |
| 700 | 1 | |a Solomon, Scott D. |4 aut | |
| 700 | 1 | |a Škrha, Jan |4 aut | |
| 700 | 1 | |a Topsever, Pinar |4 aut | |
| 700 | 1 | |a Vilsbøll, Tina |4 aut | |
| 700 | 1 | |a Wilding, John |4 aut | |
| 700 | 1 | |a Standl, Eberhard |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiovascular diabetology |d London : BioMed Central, 2002 |g 22(2023), 1 vom: 16. März |w (DE-627)SPR028533577 |w (DE-600)2093769-6 |x 1475-2840 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:16 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12933-023-01788-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 1 |b 16 |c 03 | ||